Clinical trial
A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial
NCT01231412 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial
- Lead sponsor
- Fred Hutchinson Cancer Center
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 30, 2010
- Completion date
- June 30, 2017
- Enrollment
- 174 (actual)
- Sites
- 11
Conditions
As the registry lists them; a condition with its own page is linked.
acute lymphoblastic leukemia, acute myeloid leukemia, aggressive non-hodgkin lymphoma, chronic lymphocytic leukemia, diffuse large b-cell lymphoma, hematopoietic and lymphoid cell neoplasm, indolent non-hodgkin lymphoma, mantle cell lymphoma, myelodysplastic syndrome, myeloproliferative neoplasm, prolymphocytic leukemia, recurrent chronic lymphocytic leukemia, recurrent plasma cell myeloma, refractory chronic lymphocytic leukemia, refractory chronic myelogenous leukemia, bcr-abl1 positive, refractory hodgkin lymphoma, small lymphocytic lymphoma, t-cell chronic lymphocytic leukemia, waldenstrom macroglobulinemia